Under the arrangement, Boston Scientific will gain access to Surgi- Vision’s development capabilities and will obtain a license to Surgi-Vision’s intellectual property for potential use in its implantable cardiac devices. The two companies will work jointly to develop a commercial application of Surgi-Vision’s technology.
Fred Colen, executive vice president, operations and technology, Boston Scientific Cardiac Rhythm Management, said: “Surgi-Vision’s technology, when combined with our history of innovation, should move development of MRI-safe cardiac devices closer to reality.”